Patents by Inventor Weijun Cheng

Weijun Cheng has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210180066
    Abstract: RNA interference (RNAi) triggers and RNAi trigger conjugates for inhibiting the expression of Hif2? (EPAS1) gene are described. Pharmaceutical compositions comprising one or more Hif2? RNAi triggers optionally with one or more additional therapeutics are also described. Delivery of the described Hif2? RNAi triggers to tumor cells in vivo provides for inhibition of Hif2? gene expression and treatment of cancer.
    Type: Application
    Filed: February 19, 2021
    Publication date: June 17, 2021
    Inventors: So Wong, David L. Lewis, David B. Rozema, Darren H. Wakefield, Steven B. Kanner, Weijun Cheng, Lauren J. Almeida, Andrei V. Blokhin, Jeffrey C. Carlson, Anthony L. Nicholas, Aaron Almeida, Jonathan D. Benson, Justin Woods
  • Patent number: 10927373
    Abstract: RNA interference (RNAi) triggers and RNAi trigger conjugates for inhibiting the expression of Hif2? (EPAS1) gene are described. Pharmaceutical compositions comprising one or more Hif2? RNAi triggers optionally with one or more additional therapeutics are also described. Delivery of the described Hif2? RNAi triggers to tumor cells in vivo provides for inhibition of Hif2? gene expression and treatment of cancer.
    Type: Grant
    Filed: April 16, 2018
    Date of Patent: February 23, 2021
    Assignee: Arrowhead Pharmaceuticals, Inc.
    Inventors: So Wong, David L. Lewis, David B. Rozema, Darren H. Wakefield, Steven B. Kanner, Weijun Cheng, Lauren J. Almeida, Andrei V. Blokhin, Jeffrey C. Carlson, Anthony L. Nicholas, Aaron Almeida, Jonathan D. Benson, Justin Woods
  • Publication number: 20190062748
    Abstract: The present invention is directed compositions for delivery of RNA interference (RNAi) triggers to integrin positive tumor cells in vivo. The compositions comprise RGD ligand-targeted amphipathic membrane active polyamines reversibly modified with enzyme cleavable dipeptide-amidobenzyl-carbonate masking agents. Modification masks membrane activity of the polymer while reversibility provides physiological responsiveness. The reversibly modified polyamines (dynamic polyconjugate or conjugate) are further covalently linked to an RNAi trigger.
    Type: Application
    Filed: November 13, 2018
    Publication date: February 28, 2019
    Inventors: David B. Rozema, So Wong, Weijun Cheng, Aaron M. Almeida, Andrei V. Blokhin, Jeffrey C. Carlson
  • Publication number: 20180230470
    Abstract: RNA interference (RNAi) triggers and RNAi trigger conjugates for inhibiting the expression of Hif2? (EPAS1) gene are described. Pharmaceutical compositions comprising one or more Hif2? RNAi triggers optionally with one or more additional therapeutics are also described. Delivery of the described Hif2? RNAi triggers to tumor cells in vivo provides for inhibition of Hif2? gene expression and treatment of cancer.
    Type: Application
    Filed: April 16, 2018
    Publication date: August 16, 2018
    Inventors: So Wong, David L. Lewis, David B. Rozema, Darren H. Wakefield, Steven B. Kanner, Weijun Cheng, Lauren J. Almeida, Andrei V. Blokhin, Jeffrey C. Carlson, Anthony L. Nicholas, Aaron Almeida, Jonathan D. Benson, Justin Woods
  • Patent number: 9976141
    Abstract: RNA interference (RNAi) triggers and RNAi trigger conjugates for inhibiting the expression of Hif2? (EPAS1) gene are described. Pharmaceutical compositions comprising one or more Hif2? RNAi triggers optionally with one or more additional therapeutics are also described. Delivery of the described Hif2? RNAi triggers to tumor cells in vivo provides for inhibition of Hif2? gene expression and treatment of cancer.
    Type: Grant
    Filed: May 27, 2016
    Date of Patent: May 22, 2018
    Assignee: Arrowhead Pharmaceuticals, Inc.
    Inventors: So Wong, David L. Lewis, David B. Rozema, Darren H. Wakefield, Steven B. Kanner, Weijun Cheng, Lauren J. Almeida, Andrei V. Blokhin, Jeffrey C. Carlson, Anthony L. Nicholas, Aaron Almeida, Jonathan D. Benson, Justin Woods
  • Publication number: 20170022497
    Abstract: The present invention is directed compositions for delivery of RNA interference (RNAi) triggers to integrin positive tumor cells in vivo. The compositions comprise RGD ligand-targeted amphipathic membrane active polyamines reversibly modified with enzyme cleavable dipeptide-amidobenzyl-carbonate masking agents. Modification masks membrane activity of the polymer while reversibility provides physiological responsiveness. The reversibly modified polyamines (dynamic polyconjugate or conjugate) are further covalently linked to an RNAi trigger.
    Type: Application
    Filed: September 28, 2016
    Publication date: January 26, 2017
    Inventors: David B. Rozema, So Wong, Weijun Cheng, Aaron M. Almeida, Andrei V. Blokhin, Jeffrey C. Carlson
  • Publication number: 20160348107
    Abstract: RNA interference (RNAi) triggers and RNAi trigger conjugates for inhibiting the expression of Hif2? (EPAS1) gene are described. Pharmaceutical compositions comprising one or more Hif2? RNAi triggers optionally with one or more additional therapeutics are also described. Delivery of the described Hif2? RNAi triggers to tumor cells in vivo provides for inhibition of Hif2? gene expression and treatment of cancer.
    Type: Application
    Filed: May 27, 2016
    Publication date: December 1, 2016
    Inventors: So Wong, David L. Lewis, David B. Rozema, Darren H. Wakefield, Steven B. Kanner, Weijun Cheng, Lauren J. Almeida, Andrei V. Blokhin, Jeffrey C. Carlson, Anthony L. Nicholas, Aaron Almeida, Jonathan D. Benson, Justin Woods
  • Patent number: 9487556
    Abstract: The present invention is directed compositions for delivery of RNA interference (RNAi) triggers to integrin positive tumor cells in vivo. The compositions comprise RGD ligand-targeted amphipathic membrane active polyamines reversibly modified with enzyme cleavable dipeptide-amidobenzyl-carbonate masking agents. Modification masks membrane activity of the polymer while reversibility provides physiological responsiveness. The reversibly modified polyamines (dynamic polyconjugate or conjugate) are further covalently linked to an RNAi trigger.
    Type: Grant
    Filed: August 6, 2014
    Date of Patent: November 8, 2016
    Assignee: Arrowhead Pharmaceuticals, Inc.
    Inventors: Weijun Cheng, So Wong, Aaron M. Almeida, David B. Rozema, Andrei V. Blokhin, Jeffrey C. Carlson
  • Publication number: 20150045573
    Abstract: The present invention is directed compositions for delivery of RNA interference (RNAi) triggers to integrin positive tumor cells in vivo. The compositions comprise RGD ligand-targeted amphipathic membrane active polyamines reversibly modified with enzyme cleavable dipeptide-amidobenzyl-carbonate masking agents. Modification masks membrane activity of the polymer while reversibility provides physiological responsiveness. The reversibly modified polyamines (dynamic polyconjugate or conjugate) are further covalently linked to an RNAi trigger.
    Type: Application
    Filed: August 6, 2014
    Publication date: February 12, 2015
    Inventors: Weijun Cheng, So Wong, Aaron M. Almeida, David B. Rozema, Andrei V. Blokhin, Jeffrey C. Carlson